Transgene Biotek is currently trading at Rs. 2.54, down by 0.13 points or 4.87% from its previous closing of Rs. 2.67 on the BSE.
The scrip opened at Rs. 2.80 and has touched a high and low of Rs. 2.80 and Rs. 2.54 respectively. So far 6555 shares were traded on the counter.
The BSE group ‘XT’ stock of face value Rs. 10 has touched a 52 week high of Rs. 6.08 on 23-Jan-2019 and a 52 week low of Rs. 2.43 on 28-Aug-2019.
Last one week high and low of the scrip stood at Rs. 2.80 and Rs. 2.43 respectively. The current market cap of the company is Rs. 19.25 crore.
The promoters holding in the company stood at 23.64%, while Non-Institutions held 76.36% stake in the company.
Securities and Exchange Board of India (SEBI) has barred Transgene Biotek and its directors from securities market in a case related to fund diversion through global depository receipts by the firm. Besides, Transgene will continue the measures to recall outstanding amount of $38.5 million and bring the money back into its bank account in India within a period of one year from the date of this order.
The regulator further directed the firm to continue to be restrained from the markets till the compliance of the direction and thereafter for an additional period of two years from the date of bringing back the money.
Transgene Biotek (TBL) is engaged in manufacturing drugs.